The first screening dedicated to the risk evaluation of Thrombosis associated with oral contraceptives
More than 100 million women worldwide use combined oral contraceptives (CCs), increasing their risk of thromboembolic disorders. The risk of thromboembolism increases with all CCs and especially with the latest generation of pills, the most commonly used. This risk may be increased in the presence of different genetic variants. Approximately 400 cases of thrombosis and 45 cases of pulmonary embolism related to CCs are reported each year in Switzerland (Source: Swissmedic). This also results in a significant cost to the health care system.